The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Nature, Published online: 30 October 2019; doi:10.1038/s41586-019-1694-1

Treatment of KRASG12C-mutant cancer cells with the KRAS(G12C) inhibitor AMG 510 leads to durable response in mice, and anti-tumour activity in patients suggests that AMG 510 could be effective in patients for whom treatments are currently lacking.

Comments

Popular posts from this blog

Photo Of The Day By Valerie Millett